// App-Quantinova.ai

TCT-642 : The Comparative Effectiveness and Safety of Cangrelor vs. In- lab Glycoprotein IIb/IIIa Inhibitor (GPI) in Patients Undergoing Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)

Researchers

Presenter

  • Saifullah Siddiqui

Principal Investigators

  • Milan Seth

  • Devraj Sukul

  • Ryan Madder

  • Maged Rizk

  • Eric Walchak

  • Cyril Ruwende

  • Frank Saltiel

  • Mark Zainea

  • Hameem Changezi

  • Hitinder Gurm

Medical Centers

  • McLaren-Flint, Flint, Michigan, United States

  • Interventional Cardiologist, Grand Rapids, Michigan, United States

  • McLaren Macomb, Shelby Township, Michigan, United States

  • Borgess Health System, Kalamazoo, Michigan, United States

  • The University of Michigan, Ann Arbor, Michigan, United States

  • Michigan Heart - IHA, Ann Arbor, Michigan, United States

  • MidMichigan Medical Center/University of Michigan, Midland, Michigan, United States

  • Frederik Meijer Heart & Vascular Institute, Spectrum Health, Grand Rapids, Michigan, United States

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Glycosylphosphatidylinositol

Drug/Treatment

  • cangrelor

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved